{"id":"allergovac-poliplus","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions (erythema, swelling, pruritus)"},{"rate":null,"effect":"Systemic allergic reactions"},{"rate":null,"effect":"Anaphylaxis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"This polyvalent allergen extract vaccine works by inducing immune tolerance to common allergens, likely through mechanisms of T-regulatory cell expansion and shift from Th2 to Th1/Treg responses. By gradually exposing patients to increasing doses of multiple allergen extracts, the vaccine aims to reduce allergic symptoms and the need for symptomatic medications.","oneSentence":"Allergovac Poliplus is an allergen immunotherapy vaccine designed to desensitize the immune system to multiple allergens through controlled exposure.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T03:20:59.163Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Allergic rhinitis and/or allergic asthma caused by multiple allergens"}]},"trialDetails":[{"nctId":"NCT03821077","phase":"","title":"Study to Evaluate the Efficacy and Safety of \"Allergovac Poliplus\" in Polysensitized Patients With Allergic Rhinitis/Rhinoconjunctivitis, With or Without Asthma","status":"COMPLETED","sponsor":"Roxall Medicina España S.A","startDate":"2018-08-30","conditions":"Rhinitis, Allergic, Rhinoconjunctivitis","enrollment":122},{"nctId":"NCT02844842","phase":"","title":"Evaluation of Tolerability and Safety of \"Allergovac Poliplus\" in Polysensitized Patients With Rhinitis or Allergic Rhinoconjunctivitis With or Without Asthma: A Study in Daily Clinical Practice","status":"COMPLETED","sponsor":"Roxall Medicina España S.A","startDate":"2016-11-23","conditions":"Allergic Rhinitis, Rhinoconjunctivitis, Asthma","enrollment":152},{"nctId":"NCT02849249","phase":"PHASE1","title":"A Trial With Subcutaneous Immunotherapy (SCIT) in Patients With Rhinoconjunctivitis Sensitized to Olea Europaea and Phleum Pratense","status":"COMPLETED","sponsor":"Roxall Medicina España S.A","startDate":"2015-09","conditions":"Rhinoconjuntivitis","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Allergovac Poliplus","genericName":"Allergovac Poliplus","companyName":"Roxall Medicina España S.A","companyId":"roxall-medicina-espa-a-s-a","modality":"Biologic","firstApprovalDate":"","aiSummary":"Allergovac Poliplus is an allergen immunotherapy vaccine designed to desensitize the immune system to multiple allergens through controlled exposure. Used for Allergic rhinitis and/or allergic asthma caused by multiple allergens.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}